Individualized vancomycin dosing for a patient diagnosed as severe acute pancreatitis with concurrent extracorporeal membrane oxygenation and continuous veno-venous hemofiltration therapy: a case report.
- Author:
Na HE
1
,
2
;
Ying Ying YAN
3
;
Ying Qiu YING
3
;
Min YI
4
;
Gai Qi YAO
4
;
Qing Gang GE
4
;
Suo Di ZHAI
3
Author Information
1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
2. Department of Pharmaceutical Administration and Clinical Pharmacy, Peking University School of Pharmaceutical Sciences, Beijing 100191, China.
3. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
4. Intensive Care Unit, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Anti-Bacterial Agents/administration & dosage*;
Critical Illness;
Extracorporeal Membrane Oxygenation;
Female;
Hemofiltration;
Humans;
Pancreatitis/drug therapy*;
Vancomycin/administration & dosage*
- From:
Journal of Peking University(Health Sciences)
2018;50(5):915-920
- CountryChina
- Language:Chinese
-
Abstract:
Pharmacokinetic parameters can be significantly altered for acute kidney injury (AKI), extracorporeal membrane oxygenation (ECMO) and continuous veno-venous hemofiltration therapy (CVVH). Here we reported a case of individualized vancomycin dosing for a patient diagnosed as severe acute pancreatitis treated with concurrent ECMO and CVVH. A 65 kg 32-year-old woman was admitted to hospital presented with severe acute pancreatitis (SAP), respiratory failure, metabotropic acidosis and hyperkalemia. She was admitted to intensive care unit (ICU) on hospital day 1 and was initiated on CVVH. She progressed to multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS) on ICU day 2, and veno-venous ECMO was instituted. Several catheters were inserted into the body to support ECMO, CVVH and pulse indicator continuous cardiac output (PiCCO), so vancomycin was prescribed empirically on ICU day 3 for prevention of catheter-related infection. Given the residual renal function and continuous hemofiltration intensity on day 3, vancomycin bolus of 1 000 mg was prescribed, followed by a maintenance dose of 500 mg every 8 hours. On ICU day 4, a vancomycin trough serum concentration of 14.1 mg/L was obtained before the fourth dose, which was within the target range of 10-20 mg/L. By ICU day 7, vancomycin dosage was elevated to 1.0 g every 12 hours because of aggravated infection and improved kidney function. On ICU day 14, a vancomycin trough serum concentration of 17 mg/L was obtained. Her white blood cell (WBC) and neutrophil percentage (Neut%) dropped to the normal level by ICU day 19. This vancomycin regimen was successful in providing a target attainment of trough serum concentration ranging from 10-20 mg/L quickly and in controlling infection-related symptoms and signs properly. With the help of this case report we want to call attention to the clinically significant alteration in vancomycin pharmacokinetics among critically ill patients. Individualized vancomycin dosing regimens and therapeutic drug monitoring are necessary for critically ill patients receiving CVVH and ECMO to ensure that the target serum vancomycin levels are reached to adequately treat the infection and avoid nephrotoxicity.
